Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation

Bone Marrow Transplant. 1999 Aug;24(3):335-7. doi: 10.1038/sj.bmt.1701902.

Abstract

A 46-year-old white male with small cell lung cancer (SCLC) limited to the thorax developed autoimmune thrombocytopenic purpura (AITP), following a cyclophosphamide, paclitaxel and G-CSF-containing regimen for peripheral blood stem cell (PBSC) mobilization. AITP associated with small or non-small cell lung cancer has been reported. We considered that the AITP in this case may be a part of paraneoplastic syndrome, which is frequently seen in patients with SCLC. The patient received HDC and autologous PBSC transplantation (APBSCT) for SCLC and the AITP resolved following transplantation, thus supporting the concept of HDC + APBSCT for the treatment of autoimmune diseases.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Carcinoma, Small Cell / therapy*
  • Cyclophosphamide / adverse effects
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Paclitaxel / adverse effects
  • Purpura, Thrombocytopenic, Idiopathic / etiology*
  • Purpura, Thrombocytopenic, Idiopathic / therapy
  • Transplantation, Autologous

Substances

  • Cyclophosphamide
  • Paclitaxel